Biotech re­ceives award from DOD; Reg­u­la­tors ac­cept Ap­pili Ther­a­peu­tic­s' NDA

Eu­Men­tis Ther­a­peu­tics, a Boston-based biotech, has been hand­ed an award from the US De­part­ment of De­fense.

The $3 mil­lion award will be used by Eu­Men­tis to work on a small mol­e­cule for trau­mat­ic brain in­jury that aims to tar­get the N-methyl-D-as­par­tate re­cep­tor. Specif­i­cal­ly, the biotech will study three an­tag­o­nists to eval­u­ate TBI in an an­i­mal study this year. That study will be done in col­lab­o­ra­tion with a pro­fes­sor at the Uni­ver­si­ty of Penn­syl­va­nia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER